nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—acquired immunodeficiency syndrome	0.295	1	CbGaD
Valsartan—SLCO1B1—Indinavir—acquired immunodeficiency syndrome	0.0651	0.127	CbGbCtD
Valsartan—SLCO1B1—Nelfinavir—acquired immunodeficiency syndrome	0.0632	0.124	CbGbCtD
Valsartan—SLCO1B1—Ritonavir—acquired immunodeficiency syndrome	0.0572	0.112	CbGbCtD
Valsartan—SLCO1B1—Saquinavir—acquired immunodeficiency syndrome	0.0572	0.112	CbGbCtD
Valsartan—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0313	0.0612	CbGbCtD
Valsartan—ALB—Zidovudine—acquired immunodeficiency syndrome	0.03	0.0586	CbGbCtD
Valsartan—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0262	0.0512	CbGbCtD
Valsartan—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0246	0.0481	CbGbCtD
Valsartan—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0246	0.0481	CbGbCtD
Valsartan—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0223	0.0435	CbGbCtD
Valsartan—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0223	0.0435	CbGbCtD
Valsartan—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0192	0.0376	CbGbCtD
Valsartan—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0187	0.0365	CbGbCtD
Valsartan—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0169	0.033	CbGbCtD
Valsartan—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0169	0.033	CbGbCtD
Valsartan—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0162	0.0316	CbGbCtD
Valsartan—AGTR1—endothelium—acquired immunodeficiency syndrome	0.00217	0.132	CbGeAlD
Valsartan—AGTR1—blood plasma—acquired immunodeficiency syndrome	0.00193	0.117	CbGeAlD
Valsartan—SLCO1B1—blood plasma—acquired immunodeficiency syndrome	0.00184	0.112	CbGeAlD
Valsartan—SLCO1B3—vagina—acquired immunodeficiency syndrome	0.00108	0.0657	CbGeAlD
Valsartan—SLCO1B3—lung—acquired immunodeficiency syndrome	0.00102	0.0621	CbGeAlD
Valsartan—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00093	0.0565	CbGeAlD
Valsartan—AGTR1—lymphoid tissue—acquired immunodeficiency syndrome	0.000752	0.0457	CbGeAlD
Valsartan—SLCO1B1—digestive system—acquired immunodeficiency syndrome	0.000708	0.043	CbGeAlD
Valsartan—AGTR1—blood—acquired immunodeficiency syndrome	0.000707	0.043	CbGeAlD
Valsartan—SLCO1B1—blood—acquired immunodeficiency syndrome	0.000674	0.041	CbGeAlD
Valsartan—AGTR1—vagina—acquired immunodeficiency syndrome	0.000656	0.0399	CbGeAlD
Valsartan—AGTR1—lung—acquired immunodeficiency syndrome	0.00062	0.0377	CbGeAlD
Valsartan—SLCO1B3—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.000608	0.047	CbGpPWpGaD
Valsartan—AGTR1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000591	0.0457	CbGpPWpGaD
Valsartan—AGTR1—nervous system—acquired immunodeficiency syndrome	0.000574	0.0349	CbGeAlD
Valsartan—AGTR1—central nervous system—acquired immunodeficiency syndrome	0.000553	0.0336	CbGeAlD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000459	0.0355	CbGpPWpGaD
Valsartan—SLCO1B3—Recycling of bile acids and salts—ALB—acquired immunodeficiency syndrome	0.00045	0.0348	CbGpPWpGaD
Valsartan—ALB—FOXA2 and FOXA3 transcription factor networks—TAT—acquired immunodeficiency syndrome	0.000441	0.0341	CbGpPWpGaD
Valsartan—AGTR1—brain—acquired immunodeficiency syndrome	0.000439	0.0267	CbGeAlD
Valsartan—AGTR1—lymph node—acquired immunodeficiency syndrome	0.000424	0.0258	CbGeAlD
Valsartan—SLCO1B1—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.000408	0.0316	CbGpPWpGaD
Valsartan—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000358	0.0217	CbGeAlD
Valsartan—CYP2C9—blood—acquired immunodeficiency syndrome	0.000341	0.0207	CbGeAlD
Valsartan—ALB—brain—acquired immunodeficiency syndrome	0.000339	0.0206	CbGeAlD
Valsartan—AGTR1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00033	0.0255	CbGpPWpGaD
Valsartan—ALB—lymph node—acquired immunodeficiency syndrome	0.000327	0.0199	CbGeAlD
Valsartan—AGTR1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00031	0.024	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000308	0.0238	CbGpPWpGaD
Valsartan—SLCO1B1—Recycling of bile acids and salts—ALB—acquired immunodeficiency syndrome	0.000303	0.0234	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	0.000295	0.0228	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000278	0.0215	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000251	0.0194	CbGpPWpGaD
Valsartan—SLCO1B3—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	0.000235	0.0182	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000234	0.0181	CbGpPWpGaD
Valsartan—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.000225	0.0174	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	0.000223	0.0173	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	0.000223	0.0173	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	0.000217	0.0168	CbGpPWpGaD
Valsartan—AGTR1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000213	0.0164	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	0.000212	0.0164	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000186	0.0144	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000172	0.0133	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000169	0.013	CbGpPWpGaD
Valsartan—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000162	0.000994	CcSEcCtD
Valsartan—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000162	0.000993	CcSEcCtD
Valsartan—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000162	0.000993	CcSEcCtD
Valsartan—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000162	0.000993	CcSEcCtD
Valsartan—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000161	0.000989	CcSEcCtD
Valsartan—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000161	0.000989	CcSEcCtD
Valsartan—Rash—Didanosine—acquired immunodeficiency syndrome	0.000161	0.000987	CcSEcCtD
Valsartan—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000161	0.000986	CcSEcCtD
Valsartan—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000161	0.000986	CcSEcCtD
Valsartan—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000161	0.000986	CcSEcCtD
Valsartan—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000161	0.000986	CcSEcCtD
Valsartan—Cough—Ritonavir—acquired immunodeficiency syndrome	0.00016	0.000982	CcSEcCtD
Valsartan—Headache—Didanosine—acquired immunodeficiency syndrome	0.00016	0.00098	CcSEcCtD
Valsartan—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00016	0.000979	CcSEcCtD
Valsartan—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00016	0.000978	CcSEcCtD
Valsartan—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000159	0.000977	CcSEcCtD
Valsartan—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000159	0.000976	CcSEcCtD
Valsartan—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000159	0.000975	CcSEcCtD
Valsartan—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000159	0.000973	CcSEcCtD
Valsartan—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000159	0.000972	CcSEcCtD
Valsartan—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000159	0.000971	CcSEcCtD
Valsartan—SLCO1B1—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	0.000158	0.0122	CbGpPWpGaD
Valsartan—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000158	0.000967	CcSEcCtD
Valsartan—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000158	0.000966	CcSEcCtD
Valsartan—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000157	0.000964	CcSEcCtD
Valsartan—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000157	0.000964	CcSEcCtD
Valsartan—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000157	0.000963	CcSEcCtD
Valsartan—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000157	0.000961	CcSEcCtD
Valsartan—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000157	0.00096	CcSEcCtD
Valsartan—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000156	0.000958	CcSEcCtD
Valsartan—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000156	0.000958	CcSEcCtD
Valsartan—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000156	0.000958	CcSEcCtD
Valsartan—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000156	0.000955	CcSEcCtD
Valsartan—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000156	0.000954	CcSEcCtD
Valsartan—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000155	0.000952	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000155	0.000951	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000155	0.012	CbGpPWpGaD
Valsartan—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000155	0.000948	CcSEcCtD
Valsartan—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000155	0.000947	CcSEcCtD
Valsartan—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000155	0.000947	CcSEcCtD
Valsartan—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000154	0.000946	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000154	0.000945	CcSEcCtD
Valsartan—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000154	0.000945	CcSEcCtD
Valsartan—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000154	0.000944	CcSEcCtD
Valsartan—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000153	0.000939	CcSEcCtD
Valsartan—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000153	0.000938	CcSEcCtD
Valsartan—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000153	0.000938	CcSEcCtD
Valsartan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.000937	CcSEcCtD
Valsartan—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000152	0.000933	CcSEcCtD
Valsartan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000152	0.000932	CcSEcCtD
Valsartan—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000152	0.000932	CcSEcCtD
Valsartan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000152	0.000929	CcSEcCtD
Valsartan—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000152	0.000929	CcSEcCtD
Valsartan—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000151	0.000928	CcSEcCtD
Valsartan—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000151	0.000928	CcSEcCtD
Valsartan—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.000151	0.0117	CbGpPWpGaD
Valsartan—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000151	0.000926	CcSEcCtD
Valsartan—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000151	0.000925	CcSEcCtD
Valsartan—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000151	0.000922	CcSEcCtD
Valsartan—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.00015	0.000922	CcSEcCtD
Valsartan—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.00015	0.000922	CcSEcCtD
Valsartan—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.00015	0.000922	CcSEcCtD
Valsartan—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.00015	0.000918	CcSEcCtD
Valsartan—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.00015	0.000918	CcSEcCtD
Valsartan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000149	0.000916	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000149	0.000915	CcSEcCtD
Valsartan—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000149	0.000913	CcSEcCtD
Valsartan—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000148	0.000908	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000148	0.000904	CcSEcCtD
Valsartan—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000147	0.000903	CcSEcCtD
Valsartan—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000147	0.000902	CcSEcCtD
Valsartan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.000901	CcSEcCtD
Valsartan—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000147	0.000901	CcSEcCtD
Valsartan—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000147	0.000901	CcSEcCtD
Valsartan—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000147	0.0009	CcSEcCtD
Valsartan—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000147	0.000899	CcSEcCtD
Valsartan—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000147	0.000898	CcSEcCtD
Valsartan—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000147	0.000898	CcSEcCtD
Valsartan—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000147	0.000898	CcSEcCtD
Valsartan—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000146	0.000896	CcSEcCtD
Valsartan—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000146	0.000895	CcSEcCtD
Valsartan—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000146	0.000894	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000146	0.0113	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000146	0.0113	CbGpPWpGaD
Valsartan—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000146	0.000892	CcSEcCtD
Valsartan—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000146	0.000891	CcSEcCtD
Valsartan—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000145	0.000887	CcSEcCtD
Valsartan—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000145	0.000887	CcSEcCtD
Valsartan—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000145	0.000886	CcSEcCtD
Valsartan—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000144	0.000885	CcSEcCtD
Valsartan—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000144	0.000885	CcSEcCtD
Valsartan—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000144	0.000884	CcSEcCtD
Valsartan—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000144	0.000883	CcSEcCtD
Valsartan—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000144	0.000881	CcSEcCtD
Valsartan—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000144	0.000879	CcSEcCtD
Valsartan—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000144	0.000879	CcSEcCtD
Valsartan—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000144	0.000879	CcSEcCtD
Valsartan—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000143	0.000878	CcSEcCtD
Valsartan—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000143	0.000876	CcSEcCtD
Valsartan—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000143	0.000875	CcSEcCtD
Valsartan—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000143	0.000874	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000143	0.000873	CcSEcCtD
Valsartan—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000142	0.000872	CcSEcCtD
Valsartan—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000142	0.000869	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000142	0.011	CbGpPWpGaD
Valsartan—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000142	0.000868	CcSEcCtD
Valsartan—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000866	CcSEcCtD
Valsartan—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000141	0.000866	CcSEcCtD
Valsartan—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000865	CcSEcCtD
Valsartan—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000141	0.000864	CcSEcCtD
Valsartan—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000141	0.000863	CcSEcCtD
Valsartan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.00086	CcSEcCtD
Valsartan—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00014	0.000859	CcSEcCtD
Valsartan—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00014	0.000858	CcSEcCtD
Valsartan—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.00014	0.000858	CcSEcCtD
Valsartan—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.00014	0.000858	CcSEcCtD
Valsartan—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.00014	0.000857	CcSEcCtD
Valsartan—Rash—Stavudine—acquired immunodeficiency syndrome	0.00014	0.000857	CcSEcCtD
Valsartan—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.00014	0.000856	CcSEcCtD
Valsartan—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00014	0.000856	CcSEcCtD
Valsartan—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000139	0.000854	CcSEcCtD
Valsartan—Headache—Stavudine—acquired immunodeficiency syndrome	0.000139	0.000851	CcSEcCtD
Valsartan—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000139	0.000851	CcSEcCtD
Valsartan—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000139	0.000849	CcSEcCtD
Valsartan—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000139	0.000848	CcSEcCtD
Valsartan—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000138	0.000847	CcSEcCtD
Valsartan—Rash—Abacavir—acquired immunodeficiency syndrome	0.000138	0.000844	CcSEcCtD
Valsartan—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000138	0.000843	CcSEcCtD
Valsartan—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000138	0.000843	CcSEcCtD
Valsartan—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000138	0.000843	CcSEcCtD
Valsartan—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000138	0.000842	CcSEcCtD
Valsartan—Headache—Abacavir—acquired immunodeficiency syndrome	0.000137	0.000838	CcSEcCtD
Valsartan—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000137	0.000837	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000137	0.000836	CcSEcCtD
Valsartan—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000136	0.000836	CcSEcCtD
Valsartan—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000136	0.000835	CcSEcCtD
Valsartan—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000136	0.00083	CcSEcCtD
Valsartan—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000829	CcSEcCtD
Valsartan—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000827	CcSEcCtD
Valsartan—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000135	0.000826	CcSEcCtD
Valsartan—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000825	CcSEcCtD
Valsartan—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000824	CcSEcCtD
Valsartan—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000135	0.000824	CcSEcCtD
Valsartan—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000134	0.00082	CcSEcCtD
Valsartan—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000819	CcSEcCtD
Valsartan—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000134	0.000818	CcSEcCtD
Valsartan—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000133	0.000816	CcSEcCtD
Valsartan—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000133	0.000812	CcSEcCtD
Valsartan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000132	0.000809	CcSEcCtD
Valsartan—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000132	0.000809	CcSEcCtD
Valsartan—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000132	0.000808	CcSEcCtD
Valsartan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000132	0.000808	CcSEcCtD
Valsartan—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000132	0.000807	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000131	0.000805	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	0.000131	0.0102	CbGpPWpGaD
Valsartan—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000131	0.000803	CcSEcCtD
Valsartan—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.000799	CcSEcCtD
Valsartan—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.00013	0.000798	CcSEcCtD
Valsartan—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00013	0.000795	CcSEcCtD
Valsartan—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.000793	CcSEcCtD
Valsartan—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000129	0.000793	CcSEcCtD
Valsartan—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000129	0.000791	CcSEcCtD
Valsartan—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000129	0.000789	CcSEcCtD
Valsartan—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000129	0.000788	CcSEcCtD
Valsartan—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000129	0.000788	CcSEcCtD
Valsartan—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000129	0.000788	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000128	0.00993	CbGpPWpGaD
Valsartan—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000128	0.000785	CcSEcCtD
Valsartan—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000128	0.000785	CcSEcCtD
Valsartan—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000128	0.000785	CcSEcCtD
Valsartan—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000127	0.000781	CcSEcCtD
Valsartan—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000127	0.000778	CcSEcCtD
Valsartan—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000127	0.000777	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000126	0.00975	CbGpPWpGaD
Valsartan—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000125	0.000768	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000125	0.000768	CcSEcCtD
Valsartan—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000125	0.000764	CcSEcCtD
Valsartan—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000125	0.000763	CcSEcCtD
Valsartan—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000762	CcSEcCtD
Valsartan—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000124	0.000762	CcSEcCtD
Valsartan—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000757	CcSEcCtD
Valsartan—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000123	0.000756	CcSEcCtD
Valsartan—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000123	0.000751	CcSEcCtD
Valsartan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000123	0.000751	CcSEcCtD
Valsartan—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000123	0.000751	CcSEcCtD
Valsartan—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000123	0.000751	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	0.000122	0.00947	CbGpPWpGaD
Valsartan—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.000749	CcSEcCtD
Valsartan—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000122	0.000744	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000122	0.0094	CbGpPWpGaD
Valsartan—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000122	0.000744	CcSEcCtD
Valsartan—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000121	0.000744	CcSEcCtD
Valsartan—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000121	0.000742	CcSEcCtD
Valsartan—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000121	0.00074	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00012	0.0093	CbGpPWpGaD
Valsartan—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00012	0.000734	CcSEcCtD
Valsartan—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.00012	0.000733	CcSEcCtD
Valsartan—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000119	0.000731	CcSEcCtD
Valsartan—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.000729	CcSEcCtD
Valsartan—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000119	0.000728	CcSEcCtD
Valsartan—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000119	0.000727	CcSEcCtD
Valsartan—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000119	0.000726	CcSEcCtD
Valsartan—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000118	0.000726	CcSEcCtD
Valsartan—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000118	0.000723	CcSEcCtD
Valsartan—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000118	0.000721	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	0.000117	0.00902	CbGpPWpGaD
Valsartan—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000116	0.000712	CcSEcCtD
Valsartan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000116	0.00071	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000115	0.0089	CbGpPWpGaD
Valsartan—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000115	0.000702	CcSEcCtD
Valsartan—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000702	CcSEcCtD
Valsartan—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000115	0.000701	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000114	0.00884	CbGpPWpGaD
Valsartan—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.000698	CcSEcCtD
Valsartan—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000114	0.000698	CcSEcCtD
Valsartan—Rash—Indinavir—acquired immunodeficiency syndrome	0.000113	0.000692	CcSEcCtD
Valsartan—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000113	0.000692	CcSEcCtD
Valsartan—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000113	0.000689	CcSEcCtD
Valsartan—Headache—Indinavir—acquired immunodeficiency syndrome	0.000112	0.000688	CcSEcCtD
Valsartan—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000112	0.000686	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000111	0.00859	CbGpPWpGaD
Valsartan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000111	0.000679	CcSEcCtD
Valsartan—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000676	CcSEcCtD
Valsartan—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.00067	CcSEcCtD
Valsartan—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000666	CcSEcCtD
Valsartan—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.00066	CcSEcCtD
Valsartan—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000108	0.000659	CcSEcCtD
Valsartan—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.000656	CcSEcCtD
Valsartan—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.000654	CcSEcCtD
Valsartan—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.000654	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	0.000107	0.00824	CbGpPWpGaD
Valsartan—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000106	0.000652	CcSEcCtD
Valsartan—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000651	CcSEcCtD
Valsartan—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.00065	CcSEcCtD
Valsartan—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000649	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000104	0.00805	CbGpPWpGaD
Valsartan—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000634	CcSEcCtD
Valsartan—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000631	CcSEcCtD
Valsartan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.000628	CcSEcCtD
Valsartan—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000626	CcSEcCtD
Valsartan—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000625	CcSEcCtD
Valsartan—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000625	CcSEcCtD
Valsartan—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000622	CcSEcCtD
Valsartan—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000621	CcSEcCtD
Valsartan—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000101	0.000616	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.0001	0.00774	CbGpPWpGaD
Valsartan—Dizziness—Ritonavir—acquired immunodeficiency syndrome	9.91e-05	0.000607	CcSEcCtD
Valsartan—Asthenia—Lamivudine—acquired immunodeficiency syndrome	9.87e-05	0.000605	CcSEcCtD
Valsartan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	9.87e-05	0.000605	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	9.79e-05	0.00757	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	9.79e-05	0.00757	CbGpPWpGaD
Valsartan—Pruritus—Lamivudine—acquired immunodeficiency syndrome	9.74e-05	0.000596	CcSEcCtD
Valsartan—Nausea—Delavirdine—acquired immunodeficiency syndrome	9.63e-05	0.00059	CcSEcCtD
Valsartan—Dizziness—Saquinavir—acquired immunodeficiency syndrome	9.54e-05	0.000584	CcSEcCtD
Valsartan—Vomiting—Ritonavir—acquired immunodeficiency syndrome	9.53e-05	0.000584	CcSEcCtD
Valsartan—Rash—Ritonavir—acquired immunodeficiency syndrome	9.45e-05	0.000579	CcSEcCtD
Valsartan—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	9.44e-05	0.000578	CcSEcCtD
Valsartan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	9.42e-05	0.000577	CcSEcCtD
Valsartan—Headache—Ritonavir—acquired immunodeficiency syndrome	9.39e-05	0.000575	CcSEcCtD
Valsartan—Vomiting—Saquinavir—acquired immunodeficiency syndrome	9.17e-05	0.000562	CcSEcCtD
Valsartan—Dizziness—Lamivudine—acquired immunodeficiency syndrome	9.1e-05	0.000557	CcSEcCtD
Valsartan—Rash—Saquinavir—acquired immunodeficiency syndrome	9.1e-05	0.000557	CcSEcCtD
Valsartan—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	9.09e-05	0.000557	CcSEcCtD
Valsartan—Headache—Saquinavir—acquired immunodeficiency syndrome	9.04e-05	0.000554	CcSEcCtD
Valsartan—Nausea—Ritonavir—acquired immunodeficiency syndrome	8.9e-05	0.000545	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.77e-05	0.00678	CbGpPWpGaD
Valsartan—Vomiting—Lamivudine—acquired immunodeficiency syndrome	8.75e-05	0.000536	CcSEcCtD
Valsartan—Rash—Lamivudine—acquired immunodeficiency syndrome	8.68e-05	0.000531	CcSEcCtD
Valsartan—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	8.67e-05	0.000531	CcSEcCtD
Valsartan—Headache—Lamivudine—acquired immunodeficiency syndrome	8.62e-05	0.000528	CcSEcCtD
Valsartan—Nausea—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.000525	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	8.5e-05	0.00657	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	8.47e-05	0.00655	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL4—acquired immunodeficiency syndrome	8.4e-05	0.00649	CbGpPWpGaD
Valsartan—Nausea—Lamivudine—acquired immunodeficiency syndrome	8.17e-05	0.000501	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.93e-05	0.00613	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.83e-05	0.00606	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.46e-05	0.00577	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.46e-05	0.00577	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.45e-05	0.00576	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.28e-05	0.00563	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.1e-05	0.00549	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.71e-05	0.00519	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TAT—acquired immunodeficiency syndrome	6.6e-05	0.00511	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.59e-05	0.00509	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	6.24e-05	0.00483	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.67e-05	0.00439	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AGPS—acquired immunodeficiency syndrome	5.62e-05	0.00434	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.11e-05	0.00395	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	5.08e-05	0.00393	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.84e-05	0.00374	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	4.84e-05	0.00374	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	4.51e-05	0.00349	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.5e-05	0.00348	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.48e-05	0.00347	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TAT—acquired immunodeficiency syndrome	4.44e-05	0.00343	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.3e-05	0.00333	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.3e-05	0.00333	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.21e-05	0.00326	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.21e-05	0.00326	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.07e-05	0.00315	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	4.04e-05	0.00312	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	4.03e-05	0.00312	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.96e-05	0.00306	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.89e-05	0.00301	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.83e-05	0.00296	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.83e-05	0.00296	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.77e-05	0.00292	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	3.29e-05	0.00254	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	3.26e-05	0.00252	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.25e-05	0.00251	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	3.25e-05	0.00251	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.21e-05	0.00248	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.16e-05	0.00244	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.08e-05	0.00238	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.91e-05	0.00225	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.89e-05	0.00223	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.87e-05	0.00222	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.66e-05	0.00206	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	2.65e-05	0.00205	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.62e-05	0.00203	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	2.61e-05	0.00202	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.59e-05	0.002	CbGpPWpGaD
Valsartan—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	2.54e-05	0.00196	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.46e-05	0.0019	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.4e-05	0.00186	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.26e-05	0.00175	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.26e-05	0.00175	CbGpPWpGaD
Valsartan—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	2.16e-05	0.00167	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.14e-05	0.00165	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	2.11e-05	0.00163	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	2.08e-05	0.0016	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.76e-05	0.00136	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.74e-05	0.00134	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.72e-05	0.00133	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.72e-05	0.00133	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.69e-05	0.00131	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.67e-05	0.00129	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.67e-05	0.00129	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.65e-05	0.00128	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.55e-05	0.0012	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.52e-05	0.00117	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—acquired immunodeficiency syndrome	1.15e-05	0.000891	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.95e-06	0.000692	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.91e-06	0.000689	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	8.84e-06	0.000684	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	8.13e-06	0.000628	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—acquired immunodeficiency syndrome	7.74e-06	0.000598	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.26e-06	0.000407	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	3.62e-06	0.00028	CbGpPWpGaD
